微RNA在自身免疫性肝炎中的研究进展

doi:10.20047/j.issn1673-7210.2023.28.12

摘要
图/表
参考文献(36)
相关文章 (15)

全文: PDF (550 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要微RNA（miRNA）可通过调控多个基因的表达，潜在调节细胞功能的各个方面，进而参与生物体内的免疫与炎症反应。自身免疫性肝炎（AIH）是免疫介导的慢性炎症性肝病。近年来，miRNA通过调控多种炎症信号通路，影响炎症因子的表达，从而在AIH的免疫应答和疾病进展过程中发挥着重要的作用，一些miRNA有望成为AIH诊断和治疗的新型无创性生物标志物。本文综述miRNA在AIH中的研究进展，以期为临床诊治AIH提供新思路。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	叶雯1　　徐建良2　　杨妮2

关键词 ：自身免疫性肝炎, 微RNA, 研究进展, 生物标志物, 治疗

Abstract：MicroRNA (miRNA) can potentially regulate various aspects of cellular function by regulating the expression of multiple genes, which in turn is involved in immune and inflammatory responses in living organisms. Autoimmune hepatitis (AIH) is an immune-mediated chronic inflammatory liver disease. In recent years, miRNA has played an important role in the immune response and disease progression of AIH by regulating multiple inflammatory signaling pathways and influencing the expression of inflammatory factors. Some miRNAs are expected to become a novel non-invasive biomarker for the diagnosis and treatment of AIH. This article will review the research progress of miRNA in AIH, in order to provide new ideas for clinical diagnosis and treatment of AIH.

Key words： Autoimmune hepatitis MicroRNA Research progress Biomarkers Treatment

基金资助:湖北省中医药管理局中医药科研项目（ZY2023M003）。

通讯作者: 徐建良（1976.10-），男，博士，主任医师，硕士生导师；研究方向：中医药防治结石及肝胆病。

作者简介: 叶雯（1999.10-），女，湖北中医药大学中医临床学院2021级中医内科学专业在读硕士研究生；研究方向：中医药防治结石及肝胆病。

引用本文:

叶雯1　　徐建良2　　杨妮2. 微RNA在自身免疫性肝炎中的研究进展[J]. 中国医药导报, 2023, 20(28): 58-61.
YE Wen1 XU Jianliang2 YANG Ni2. Research progress of miRNA in autoimmune hepatitis#br#. 中国医药导报, 2023, 20(28): 58-61.

链接本文:

https://www.yiyaodaobao.com.cn/CN/10.20047/j.issn1673-7210.2023.28.12 或 https://www.yiyaodaobao.com.cn/CN/Y2023/V20/I28/58

[1] 马雄，王绮夏，肖潇，等.自身免疫性肝炎诊断和治疗指南（2021）[J].临床肝胆病杂志，2022，38（1）：42-49.
[2] 胡明礼，王绮夏，马雄.自身免疫性肝炎发病机制进展与临床干预新靶点[J].临床肝胆病杂志，2022，38（4）：743-747.
[3] Bischoff S，Yesmembetov K，Antoni C，et al. Autoimmune hepatitis：a review of established and evolving treatments [J]. J Gastrointestin Liver Dis，2020，29（3）：429-443.
[4] 刘怀鄂，钱建丹，张驰，等.新型无创技术在指导自身免疫性肝炎诊疗中的作用[J].临床肝胆病杂志，2022，38（4）：908-912.
[5] Wang X，He Y，Mackowiak B，et al. MicroRNAs as regulators，biomarkers and therapeutic targets in liver diseases [J]. Gut，2021，70（4）：784-795.
[6] Huang C，Xing X，Xiang X，et al. MicroRNAs in autoimmune liver diseases：from diagnosis to potential therapeutic targets [J]. Biomed Pharmacother，2020，130：110558.
[7] Chen L，Heikkinen L，Wang C，et al. Trends in the development of miRNA bioinformatics tools [J]. Brief Bioinform，2019， 20（5）：1836-1852.
[8] Kabekkodu SP，Shukla V，Varghese VK，et al. Clustered miRNAs and their role in biological functions and diseases [J]. Biol Rev Camb Philos Soc，2018，93（4）：1955-1986.
[9] Cho S，Dong J，Lu LF. Cell-intrinsic and-extrinsic roles of miRNAs in regulating T cell immunity [J]. Immunol Rev，2021，304（1）：126-140.
[10] Zhao J，Chu F，Xu H，et al. C/EBPα/miR-7 controls CD4+ T-cell activation and function and orchestrates experimental autoimmune hepatitis in mice [J]. Hepatology，2021，74（1）：379-396.
[11] Xia G，Wu S，Wang X，et al. Inhibition of microRNA-155 attenuates concanavalin-A-induced autoimmune hepatitis by regulating Treg/Th17 cell differentiation [J]. Can J Physiol Pharmacol，2018，96（12）：1293-1300.
[12] 董雯迪，张海蓉，李瑞，等.调节性T淋巴细胞/辅助性T淋巴细胞17在自身免疫性肝炎发生发展中的作用机制及其相关治疗靶点[J].临床肝胆病杂志，2021，37（10）：2456-2460.
[13] Borbet TC，Hines MJ，Koralov SB. MicroRNA regulation of B cell receptor signaling [J]. Immunol Rev，2021，304（1）：111-125.
[14] Schell SL，Rahman ZSM. miRNA-mediated control of B cell responses in immunity and SLE [J]. Front Immunol，2021， 12：683710.
[15] Liu Y，Chen H，Hao J，et al. Characterization and functional prediction of the microRNAs differentially expressed in a mouse model of concanavalin A-induced autoimmune hepatitis [J]. Int J Med Sci，2020，17（15）：2312-2327.
[16] Yan Y，Qin D，Hu B，et al. Deletion of miR-126a promotes hepatic aging and inflammation in a mouse model of chol- estasis [J]. Mol Ther Nucleic Acids，2019，16：494-504.
[17] 葛巍，王海燕，刘妙华，等.姜黄素对自身免疫性肝炎小鼠miRNA-mRNA表达谱的调控作用[J].中华中医药杂志，2022，37（5）：2547-2552.
[18] Hao R，Ge J，Li F，et al. MiR-34a-5p/sirt1 axis：a novel pathway for puerarin-mediated hepatoprotection against benzo（a）pyrene [J]. Free Radic Biol Med，2022，186：53-65.
[19] Yang F，Fan X，Liu Y，et al. Long noncoding RNA and circular RNA expression profiles of monocyte-derived dendritic cells in autoimmune hepatitis [J]. Front Pharmacol，2021，12：792138.
[20] Ju B，Nie Y，Yang X，et al. miR-193a/b-3p relieves hepatic fibrosis and restrains proliferation and activation of hepatic stellate cells [J]. J Cell Mol Med，2019，23（6）：3824- 3832.
[21] Tu H，Chen D，Cai C，et al. microRNA-143-3p attenuated development of hepatic fibrosis in autoimmune hepatitis through regulation of TAK1 phosphorylation [J]. J Cell Mol Med，2020，24（2）：1256-1267.
[22] Wang H，Wang Z，Wang Y，et al. miRNA-130b-5p promotes hepatic stellate cell activation and the development of liver fibrosis by suppressing SIRT4 expression [J]. J Cell Mol Med，2021，25（15）：7381-7394.
[23] Ma Y，Yuan X，Han M，et al. miR-98-5p as a novel biomarker suppress liver fibrosis by targeting TGFβ receptor 1 [J]. Hepatol Int，2022，16（3）：614-626.
[24] Zhou QY，Yang HM，Liu JX，et al. MicroRNA-497 induced by Clonorchis sinensis enhances the TGF-β/Smad signaling pathway to promote hepatic fibrosis by targeting Smad7 [J]. Parasit Vectors，2021，14（1）：472.
[25] 冯锦.miR-20b介导的Notch信号通路对自身免疫性肝炎模型小鼠巨噬细胞的免疫调节及机制的研究[J].免疫学杂志，2022，38（5）：378-385.
[26] Czaja AJ. Examining micro-ribonucleic acids as diagnostic and therapeutic prospects in autoimmune hepatitis [J]. Expert Rev Clin Immunol，2022，18（6）：591-607.
[27] Czaja AJ. Epigenetic aspects and prospects in autoimmune hepatitis [J]. Front Immunol，2022，13：921765.
[28] Xue X，Wang J，Fu K，et al. The role of miR-155 on liver diseases by modulating immunity，inflammation and tumorigenesis [J]. Int Immunopharmacol，2023，116：109775.
[29] Blaya D，Aguilar-Bravo B，Hao F，et al. Expression of microRNA-155 in inflammatory cells modulates liver injury [J]. Hepatology，2018，68（2）：691-706.
[30] Kostallari E，Valainathan S，Biquard L，et al. Role of extracellular vesicles in liver diseases and their therapeutic potential [J]. Adv Drug Deliv Rev，2021，175：113816.
[31] Abe K，Suzuki R，Fujita M，et al. Circulating extracellular vesicle-encapsulated microRNA-557 induces a proinflammatory immune response and serves as a diagnostic or relapse marker in autoimmune hepatitis [J]. Hepatol Res，2022， 52（12）：1034-1049.
[32] Lin F，Chen W，Zhou J，et al. Mesenchymal stem cells protect against ferroptosis via exosome-mediated stabilization of SLC7A11 in acute liver injury [J]. Cell Death Dis，2022， 13（3）：271.
[33] Sameri MJ，Savari F，Hoseinynejad K，et al. The hepato-protective effect of H2S-modified and non-modified mesenchymal stem cell exosomes on liver ischemia-reperfusion injury in mice：the role of MALAT1 [J]. Biochem Biophys Res Commun，2022，635：194-202.
[34] Lin D，Chen H，Xiong J，et al. Mesenchymal stem cells exosomal let-7a-5p improve autophagic flux and alleviate liver injury in acute-on-chronic liver failure by promoting nuclear expression of TFEB [J]. Cell Death Dis，2022，13（10）：865.
[35] Wang C，Zhou H，Wu R，et al. Mesenchymal stem cell-derived exosomes and non-coding RNAs：regulatory and therapeutic role in liver diseases [J]. Biomed Pharmacother，2023， 157：114040.
[36] Lu FB，Chen DZ，Chen L，et al. Attenuation of experimental autoimmune hepatitis in mice with bone mesenchymal stem cell-derived exosomes carrying MicroRNA-223-3p [J]. Mol Cells，2019，42（12）：906-918.